• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations.膝关节骨关节炎中重度疼痛患者的多模态多学科管理:需要满足患者的期望。
Drugs. 2022 Sep;82(13):1347-1355. doi: 10.1007/s40265-022-01773-5. Epub 2022 Sep 16.
2
A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting.关于欧洲骨质疏松症与骨关节炎临床与经济学会(ESCEO)膝关节骨关节炎管理算法的共识声明——从循证医学到现实环境
Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.
3
Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys.局部用非甾体抗炎药治疗骨关节炎的疗效与安全性:来自实际应用试验和调查的证据。
Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S18-21. doi: 10.1016/j.semarthrit.2015.11.007. Epub 2015 Dec 2.
4
Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis.中欧专家对修订后的膝骨关节炎 ESCEO 管理算法的认可。
Rheumatol Int. 2019 Jul;39(7):1117-1123. doi: 10.1007/s00296-019-04332-6. Epub 2019 May 25.
5
Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.使用透明质酸钠凝胶20进行膝关节腔内粘弹性补充治疗骨关节炎:一项循证分析。
Ont Health Technol Assess Ser. 2005;5(10):1-66. Epub 2005 Jun 1.
6
WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee.撤回:用于治疗膝关节骨关节炎的非阿司匹林非甾体抗炎药。
Cochrane Database Syst Rev. 2007 Jul 18;2006(1):CD000142. doi: 10.1002/14651858.CD000142.pub2.
7
2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.2021 年膝关节骨关节炎管理修订算法——中国观点。
Aging Clin Exp Res. 2021 Aug;33(8):2141-2147. doi: 10.1007/s40520-021-01906-y. Epub 2021 Jun 29.
8
Commentary on recent therapeutic guidelines for osteoarthritis.骨关节炎近期治疗指南述评
Semin Arthritis Rheum. 2015 Jun;44(6):611-7. doi: 10.1016/j.semarthrit.2014.12.003. Epub 2014 Dec 24.
9
Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys.透明质酸治疗骨关节炎的疗效与安全性:来自真实环境试验和调查的证据。
Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S28-33. doi: 10.1016/j.semarthrit.2015.11.008. Epub 2015 Dec 2.
10
A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes.氨基葡萄糖治疗膝骨关节炎的综述:为何专利结晶硫酸氨基葡萄糖应与其他氨基葡萄糖区分开来以实现最佳临床效果。
Curr Med Res Opin. 2016 Jun;32(6):997-1004. doi: 10.1185/03007995.2016.1154521. Epub 2016 Feb 26.

引用本文的文献

1
Complementary, alternative, and integrative medicine therapies for knee osteoarthritis: a visual analytics analysis of the research domain.膝骨关节炎的补充、替代和整合医学疗法:研究领域的可视化分析
Front Med (Lausanne). 2025 Jun 11;12:1586357. doi: 10.3389/fmed.2025.1586357. eCollection 2025.
2
Unraveling Osteoarthritis: Mechanistic Insights and Emerging Therapies Targeting Pain and Inflammation.解析骨关节炎:针对疼痛与炎症的机制见解及新兴疗法
Biomolecules. 2025 Jun 16;15(6):874. doi: 10.3390/biom15060874.
3
The role of comprehensive geriatric assessment in older patients affected by knee osteoarthritis: an exploratory randomized controlled trial.综合老年医学评估在膝骨关节炎老年患者中的作用:一项探索性随机对照试验。
Aging Clin Exp Res. 2025 May 16;37(1):155. doi: 10.1007/s40520-025-03061-0.
4
Executive Summary: Treatment of Osteoporosis and Osteoarthritis in the Oldest Old.执行摘要:高龄老年人骨质疏松症和骨关节炎的治疗
Drugs Aging. 2025 Mar;42(3):179-181. doi: 10.1007/s40266-025-01184-7. Epub 2025 Feb 24.
5
Lidocaine Shows Significant Antimicrobial Effects Against Species: An In-Vitro Study Comparing Different Combinations of Lidocaine and Clinically Used Injectables, like Steroids and Hyaluronan, in the Context of Arthritis Management.利多卡因对多种菌种显示出显著抗菌作用:一项体外研究,比较了利多卡因与临床常用注射剂(如类固醇和透明质酸)在关节炎治疗背景下的不同组合。
Biomedicines. 2025 Jan 5;13(1):106. doi: 10.3390/biomedicines13010106.
6
Genetic Biomarkers and Circulating White Blood Cells in Osteoarthritis: A Bioinformatics and Mendelian Randomization Analysis.骨关节炎中的遗传生物标志物与循环白细胞:一项生物信息学和孟德尔随机化分析
Biomedicines. 2025 Jan 2;13(1):90. doi: 10.3390/biomedicines13010090.
7
Literature Review to Understand the Burden and Current Non-surgical Management of Moderate-Severe Pain Associated with Knee Osteoarthritis.文献综述:了解与膝关节骨关节炎相关的中重度疼痛的负担及当前非手术治疗方法
Rheumatol Ther. 2024 Dec;11(6):1457-1499. doi: 10.1007/s40744-024-00720-y. Epub 2024 Oct 30.
8
Trajectories and Predictors of Weight-Bearing and Non-Weight-Bearing Pain in Knee Osteoarthritis: A 9-Year Follow-Up Study.膝关节骨关节炎负重和非负重疼痛的轨迹及预测因素:一项9年随访研究
J Pain Res. 2024 Oct 16;17:3385-3395. doi: 10.2147/JPR.S480910. eCollection 2024.
9
A Review of Current Approaches to Pain Management in Knee Osteoarthritis with a Focus on Italian Clinical Landscape.膝关节骨关节炎疼痛管理的当前方法综述:聚焦意大利临床现状
J Clin Med. 2024 Aug 31;13(17):5176. doi: 10.3390/jcm13175176.
10
Current Approaches to Four Challenging Pain Syndromes.应对四种具有挑战性疼痛综合征的当前方法。
Cureus. 2023 Sep 19;15(9):e45573. doi: 10.7759/cureus.45573. eCollection 2023 Sep.

本文引用的文献

1
Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.非甾体抗炎药和阿片类药物治疗膝和髋骨关节炎的疗效和安全性:网络荟萃分析。
BMJ. 2021 Oct 12;375:n2321. doi: 10.1136/bmj.n2321.
2
Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies.基于人群研究的全球、地区膝关节骨关节炎的患病率、发病率及危险因素
EClinicalMedicine. 2020 Nov 26;29-30:100587. doi: 10.1016/j.eclinm.2020.100587. eCollection 2020 Dec.
3
Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial.采用创新型高分子量和低分子量透明质酸制剂(HA-HL)治疗膝骨关节炎疼痛:一项随机临床试验。
Rheumatol Ther. 2021 Dec;8(4):1617-1636. doi: 10.1007/s40744-021-00363-3. Epub 2021 Aug 30.
4
A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes.塞来昔布与硫酸氨基葡萄糖联合使用具有抗炎和软骨保护作用:一项关于人骨关节炎软骨细胞的体外研究结果
Int J Mol Sci. 2021 Aug 20;22(16):8980. doi: 10.3390/ijms22168980.
5
Pharmacologic Therapy for Acute Pain.急性疼痛的药物治疗。
Am Fam Physician. 2021 Jul 1;104(1):63-72.
6
2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.2021 年膝关节骨关节炎管理修订算法——中国观点。
Aging Clin Exp Res. 2021 Aug;33(8):2141-2147. doi: 10.1007/s40520-021-01906-y. Epub 2021 Jun 29.
7
2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint.2019 年膝关节骨关节炎管理修订算法:东南亚观点。
Aging Clin Exp Res. 2021 May;33(5):1149-1156. doi: 10.1007/s40520-021-01834-x. Epub 2021 Mar 28.
8
Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis.局部用非甾体抗炎药治疗膝骨关节炎:系统评价和荟萃分析。
Phys Sportsmed. 2021 Nov;49(4):381-391. doi: 10.1080/00913847.2021.1886573. Epub 2021 Mar 4.
9
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines.膝关节骨关节炎的非手术治疗:ESCEO 和 OARSI 2019 指南比较。
Nat Rev Rheumatol. 2021 Jan;17(1):59-66. doi: 10.1038/s41584-020-00523-9. Epub 2020 Oct 28.
10
Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis.比较塞来昔布与双氯芬酸钠治疗膝骨关节炎患者的 Meta 分析。
Pain Med. 2021 Feb 23;22(2):352-362. doi: 10.1093/pm/pnaa230.

膝关节骨关节炎中重度疼痛患者的多模态多学科管理:需要满足患者的期望。

Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations.

机构信息

Geriatrics Section, Department of Internal Medicine and Geriatrics, University of Palermo, via del Vespro, 141, 90127, Palermo, Italy.

MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.

出版信息

Drugs. 2022 Sep;82(13):1347-1355. doi: 10.1007/s40265-022-01773-5. Epub 2022 Sep 16.

DOI:10.1007/s40265-022-01773-5
PMID:36112341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9512723/
Abstract

Knee osteoarthritis (OA) is one of the most common and disabling medical conditions. In the case of moderate to severe pain, a single intervention may not be sufficient to allay symptoms and improve quality of life. Examples include first-line, background therapy with symptomatic slow-acting drugs for OA (SYSADOAs) or non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) performed a review of a multimodal/multicomponent approach for knee OA therapy. This strategy is a particularly appropriate solution for the management of patients affected by knee OA, including those with pain and dysfunction reaching various thresholds at the different joints. The multimodal/multicomponent approach should be based, firstly, on different combinations of non-pharmacological and pharmacological interventions. Potential pharmacological combinations include SYSADOAs and NSAIDs, NSAIDs and weak opioids, and intra-articular treatments with SYSADOAs/NSAIDs. Based on the available evidence, most combined treatments provide benefit beyond single agents for the improvement of pain and other symptoms typical of knee OA, although further high-quality studies are required. In this work, we have therefore provided new, patient-centered perspectives for the management of knee OA, based on the concept that a multimodal, multicomponent, multidisciplinary approach, applied not only to non-pharmacological treatments but also to a combination of the currently available pharmacological options, will better meet the needs and expectations of patients with knee OA, who may present with various phenotypes and trajectories.

摘要

膝骨关节炎(OA)是最常见和最致残的医学病症之一。对于中重度疼痛患者,单一干预措施可能不足以缓解症状和改善生活质量。例如,一线、背景治疗,即使用治疗 OA 的症状缓解慢作用药物(SYSADOAs)或非甾体抗炎药(NSAIDs)。因此,欧洲临床和经济骨质疏松、骨关节炎和肌肉骨骼疾病学会(ESCEO)对膝骨关节炎治疗的多模式/多组分方法进行了回顾。对于膝骨关节炎患者的管理,这种策略是一种特别合适的解决方案,包括那些疼痛和功能障碍达到不同关节不同阈值的患者。多模式/多组分方法应首先基于非药物和药物干预的不同组合。潜在的药物组合包括 SYSADOAs 和 NSAIDs、NSAIDs 和弱阿片类药物,以及关节内 SYSADOAs/NSAIDs 治疗。基于现有证据,大多数联合治疗在改善膝骨关节炎的疼痛和其他症状方面提供了优于单一药物的益处,尽管需要进一步的高质量研究。在这项工作中,我们基于多模式、多组分、多学科方法的概念,为膝骨关节炎的管理提供了新的、以患者为中心的观点,该方法不仅应用于非药物治疗,还应用于当前可用的药物选择的联合治疗,将更好地满足具有各种表型和轨迹的膝骨关节炎患者的需求和期望。